Optimization of the Arg8−Arg9 Cleavage Site in 68Ga-Labeled Neurotensin(6−13) Analogs for NTSR1-Targeted PET Imaging of Cancer
Abstract Neurotensin receptor 1 (NTSR1) is overexpressed in many cancers and represents a promising target for PET imaging. Neurotensin (NT)-derived radiopharmaceuticals targeting NTSR1 have been widely investigated; however, their clinical translation is limited in part by rapid proteolytic degradation, particularly at the Arg8−Arg9, Pro10−Tyr11, and Tyr11−Ile12 peptide bonds. In this study, we focused on optimizing the Arg8−Arg9 cleavage site through the incorporation of non-canonical amino acids to improve metabolic stability while maintaining high receptor affinity. A series of 16 DOTA-conjugated NT(6−13) analogs containing modifications at Arg8 and/or Arg9 were synthesized by solid-phase peptide synthesis. The natGa-labeled analogs were evaluated in PC-3 cells using a competition binding assay with [125I-Tyr3]Neurotensin, and compounds with Ki values < 5 nM were selected for 68Ga-radiolabeling, PET imaging, biodistribution, and in vivo stability studies. Ga-SK01033 (Phe(3-guanidine) at Arg8) and Ga-SK02040 (NMe-Orn(Me)3 at Arg8) demonstrated Ki values of 3.35 ± 0.32 and 4.34 ± 1.16 nM, respectively. Both peptides were labeled with 68Ga in 35.0−60.9% decay-corrected radiochemical yields, >108 GBq/μmol molar activity, and >97% radiochemical purity. Despite good binding affinity, [68Ga]Ga-SK01033 exhibited poor in vivo stability and negligible tumor uptake (<1 % ID/g at 1 h p.i., no intact tracer detected at 15 min p.i.). In contrast, [68Ga]Ga-SK02040 displayed improved metabolic stability, with 70.3 ± 5.11% intact tracer at 15 min p.i., resulting in tumor uptake of 11.1 ± 2.64 % ID/g at 1 h p.i. and 9.39 ± 2.64 % ID/g at 3 h p.i. Co-injection of excess natGa-SK02040 reduced tumor uptake by 91.2%, confirming NTSR1-mediated targeting. Overall, these findings demonstrate that while Phe(3-guanidine) substitution improves binding affinity without enhancing stability, incorporation of NMe-Orn(Me)3 at Arg8 simultaneously enhances affinity and metabolic stability, resulting in higher tumor uptake and tumor-to-non-target contrast than previously reported [68Ga]Ga-DOTA-NT-20.3. The present study establishes NMe-Orn(Me)3 as a favorable Arg8 modification that enables the development of NT(6−13)-based PET tracers with improved in vivo performance for targeting NTSR1.
Authors
- Kuo‐Shyan Lin (ORCID: https://orcid.org/0000-0002-0739-0780)
- François Bénard (ORCID: https://orcid.org/0000-0001-7995-3581)
- Ka Yee Yee (ORCID: https://orcid.org/0000-0003-4132-8929)
- Helen Merkens (ORCID: https://orcid.org/0000-0003-1958-0167)
- Jutta Zeisler
- Joseph Lau (ORCID: https://orcid.org/0000-0002-1510-9653)
- Finnley Cookson (ORCID: https://orcid.org/0009-0007-1634-3453)
- Sheetal Pathania
- Pauline Ng
- Stefan Mair (2430112)
- Simranjeet Kaur
Institutions
- University of British Columbia (CA)
Publication Details
- Journal
- Molecular Pharmaceutics
- Published
- 2026-11-12
- DOI
- https://doi.org/10.1021/acs.molpharmaceut.6c01104
- Primary Topic
- Radiopharmaceutical Chemistry and Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of British Columbia
- BC Cancer Foundation